Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Biomea Fusion (Nasdaq: BMEA) announced that Mick Hitchcock, Ph.D., Interim CEO and board member, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 from 5:15 PM to 5:55 PM PT. Management will also host one-on-one meetings during the conference running January 12–15, 2026.
A live audio webcast of the presentation will be available on the company's Investors & Media website, with a replay posted after the live event.
Positive
- None.
Negative
- None.
News Market Reaction – BMEA
On the day this news was published, BMEA declined 1.46%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
BMEA gained 2.24% while peers showed mixed moves: CRBP -6.88%, PYXS -4.08%, KALA -7.4%, EQ +9.01%, ZNTL flat. This points to stock-specific dynamics rather than a unified biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 09 | KOL presentation | Positive | -0.7% | KOL interview and WCIRDC presentation on menin and icovamenib. |
| Dec 05 | Clinical data update | Positive | +3.9% | COVALENT-111 results showing durable glycemic and C-peptide benefits. |
| Dec 01 | Conference preview | Positive | -7.3% | Announcement of upcoming oral icovamenib presentation at WCIRDC. |
| Dec 01 | Inducement grant | Neutral | -7.3% | Inducement stock option grant under 2023 Inducement Equity Plan. |
| Nov 24 | Investor conferences | Positive | +2.9% | Participation in Piper Sandler and Evercore healthcare investor conferences. |
Recent event and conference news has produced mixed reactions, with more instances of negative moves following generally positive or neutral announcements.
Over the last month, Biomea Fusion issued several updates, including WCIRDC presentations on icovamenib and a KOL interview on Dec 9, 2025. These scientific and conference-related news items saw both gains and selloffs, suggesting investor sensitivity to broader financing and balance-sheet concerns noted in recent SEC filings. Today’s J.P. Morgan Healthcare Conference participation continues a pattern of active visibility at investor and scientific meetings rather than a discrete clinical or financial milestone.
Regulatory & Risk Context
The company has an active S-3 shelf registration dated 2025-08-05, currently noted as not effective, with an expiration on 2028-08-05. It has been used in connection with at least 2 prospectus supplements filed on 2025-10-06 and 2025-10-07, indicating prior capital-raising activity under this framework.
Market Pulse Summary
This announcement highlights Biomea Fusion’s participation at the 44th Annual J.P. Morgan Healthcare Conference, with a scheduled presentation on January 14, 2026 and one‑on‑one meetings from January 12–15. It continues a pattern of active presence at scientific and investor events following WCIRDC presentations. Given recent filings noting liquidity constraints and prior offerings, investors may watch for any strategic or financing updates around this conference and how they relate to ongoing icovamenib and BMF‑650 development.
AI-generated analysis. Not financial advice.
SAN CARLOS, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that Mick Hitchcock, Ph.D., Interim Chief Executive Officer and Board Member, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 from 5:15 PM to 5:55 PM Pacific Time. Additionally, Biomea’s management team will host one-on-one meetings throughout the conference, which will take place from January 12-15.
A live audio webcast of the presentation can be accessed here or by visiting the Investors & Media section of Biomea’s website at https://investors.biomeafusion.com/news-events/events. A replay of the webcast will be available following the live presentation.
About Biomea Fusion
Biomea Fusion is a clinical-stage biopharmaceutical company advancing oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure.
Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook.
Contact:
Meichiel Jennifer Weiss
Sr. Director of Investor Relations and Corporate Development
ir@biomeafusion.com
FAQ
When will Biomea Fusion (BMEA) present at the J.P. Morgan Healthcare Conference in 2026?
Who is presenting for Biomea Fusion (BMEA) at the January 2026 J.P. Morgan conference?
What are the conference dates for the 44th Annual J.P. Morgan Healthcare Conference where BMEA will participate?
How can investors listen to Biomea Fusion's (BMEA) J.P. Morgan presentation?
Will Biomea Fusion (BMEA) hold meetings at the J.P. Morgan Healthcare Conference?
Where can I find the replay of Biomea Fusion's (BMEA) January 14, 2026 presentation?
